Using a cohort of patients with stage IB/II/IIIA NSCLC receiving adjuvant chemotherapy, identified through population-based and medical registries in Denmark, we characterized PD-L1 expression in conjunction with EGFR and KRAS mutations, and their association with survival. Here, KRAS is linked to non-small cell lung carcinoma.